Your browser doesn't support javascript.
loading
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Italiano, Antoine; Cassier, Philippe A; Lin, Chia-Chi; Alanko, Tuomo; Peltola, Katriina J; Gazzah, Anas; Shiah, Her-Shyong; Calvo, Emiliano; Cervantes, Andrés; Roda, Desamparados; Tosi, Diego; Gao, Bo; Millward, Michael; Warburton, Lydia; Tanner, Minna; Englert, Stefan; Lambert, Stacie; Parikh, Apurvasena; Afar, Daniel E; Vosganian, Gregory; Moreno, Victor.
Afiliación
  • Italiano A; Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 3300, Bordeaux, France. a.italiano@bordeaux.unicancer.fr.
  • Cassier PA; University of Bordeaux, Bordeaux, France. a.italiano@bordeaux.unicancer.fr.
  • Lin CC; Department of Medical Oncology, Centre Leon Berard, Lyon, France.
  • Alanko T; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Peltola KJ; Docrates Cancer Center, Helsinki, Finland.
  • Gazzah A; Docrates Cancer Center, Helsinki, Finland. katriina.peltola@hus.fi.
  • Shiah HS; Comprehensive Cancer Center, Helsinki University Central Hospital, Helsinki, Finland. katriina.peltola@hus.fi.
  • Calvo E; Department of Drug Development (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Cervantes A; Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University Hospital, Taipei, Taiwan.
  • Roda D; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte-Sanchinarro, Madrid, Spain.
  • Tosi D; Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Gao B; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Millward M; Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Warburton L; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Tanner M; Medical Oncology Department, Institut du Cancer de Montpellier, Montpellier, France.
  • Englert S; Blacktown and Westmead Hospitals, Sydney, NSW, Australia.
  • Lambert S; Linear Clinical Research, University of Western Australia, Nedlands, WA, Australia.
  • Parikh A; Linear Clinical Research, University of Western Australia, Nedlands, WA, Australia.
  • Afar DE; Department of Oncology, Tampere University Hospital, Tampere, Finland.
  • Vosganian G; AbbVie Deutschland, GmbH & Co KG, Ludwigshafen, Germany.
  • Moreno V; AbbVie Inc, Redwood City, CA, USA.
Cancer Immunol Immunother ; 71(2): 417-431, 2022 Feb.
Article en En | MEDLINE | ID: mdl-34216247
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Carcinoma de Células Escamosas de Cabeza y Cuello / Neoplasias de Cabeza y Cuello / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Carcinoma de Células Escamosas de Cabeza y Cuello / Neoplasias de Cabeza y Cuello / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: Francia